Skip to content
Markets News
Stocks1 min read

EyePoint’s DURAVYU Misses Primary Endpoint in Second Wet AMD Trial

Makkler Newsroom
October 19, 2026 · Based on reporting by GlobeNewswire

LUCIA showed lower treatment burden and favorable safety, but DURAVYU did not meet the trial’s primary measure of visual acuity.

Key takeaways

  • DURAVYU did not meet LUCIA’s primary endpoint of non-inferiority in visual acuity.
  • The trial reported a 38% reduction in treatment burden and favorable safety with redosing.

EyePoint said its investigational drug DURAVYU failed to meet the primary endpoint in LUCIA, its second Phase 3 trial for wet age-related macular degeneration. The study tested whether visual acuity changes were statistically non-inferior to on-label aflibercept.

The company said key secondary endpoints were met, including a 38% reduction in treatment burden. At Week 56, 52% of eyes were free of supplemental treatment, while 71% received zero or one supplemental injection. EyePoint also reported favorable safety with redosing.

EyePoint said it will conduct further analyses of LUCIA and pooled Phase 3 data to assess next steps for DURAVYU in wet AMD. The company’s Phase 3 trials of the drug for diabetic macular edema remain underway, with topline results expected in the fourth quarter of 2027.

Topics
EYPTDURAVYU
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.